Sponsor pipeline

Zenas BioPharma (USA), LLC clinical trial pipeline

6 active trials 2 recruiting 4 Phase 3 2 disease areas 3 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Phase 2		2
Phase 3		4

NCT ID	Title	Condition	Status	Updated
Phase 3
NCT07299019	A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Recruiting	2026-10-07
NCT07067463	A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis	Multiple Sclerosis (MS) Primary Progressive	Recruiting	2026-10-05
NCT05662241	A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease	IgG4 Related Disease	Active, Not Recruiting	2026-02-04
NCT05786573	A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)	Warm Autoimmune Hemolytic Anemia	Active, Not Recruiting	2025-06-25
Phase 2
NCT06559163	A Study of Obexelimab in Patients With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Active, Not Recruiting	2026-08-18
NCT06564311	A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)	Relapsing Multiple Sclerosis	Active, Not Recruiting	2025-11-17

Get alerts when Zenas BioPharma (USA), LLC's trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.